<DOC>
	<DOCNO>NCT00785941</DOCNO>
	<brief_summary>The purpose study determine IMC-A12 safe patient , also determine best dose IMC-A12 give patient .</brief_summary>
	<brief_title>A Study IMC-A12 Every 2 Weeks Patients With Tumors Who No Longer Respond Treatment No Treatment Available</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) anti-IGF-IR monoclonal antibody IMC-A12 administer every week patient advance solid tumor longer respond standard therapy standard therapy available .</detailed_description>
	<criteria>Inclusion Criteria Patients histopathologicallydocumented , measurable , advanced primary recurrent solid tumor longer respond standard therapy standard therapy available A life expectancy &gt; 3 month Adequate hematologic function Adequate hepatic function Adequate renal function Use effective contraception , procreative potential exists . At least 28 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy ( palliative radiation therapy allow ) , open biopsy , significant traumatic injury allow adequate recovery At least 6 week must elapse nitrosoureas , mitomycin C , monoclonal antibody therapy allow adequate recovery Accessible treatment followup . Patients enrol trial must treat participate center Exclusion Criteria Any concurrent malignancy nonmelanomatous skin cancer carcinoma situ cervix . Patients previous malignancy without evidence disease â‰¥3 year allow enter trial Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month uncontrolled hypertension ( systolic blood pressure &gt; 160 mm Hg , diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1week period despite adequate medical support ) clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ National Cancer Institute { NCI } Common Terminology Criteria Adverse Events { CTCAE } , Version 3.0 , grade 3 ] asymptomatic sustain ventricular tachycardia ) psychiatric illness/social situation would compromise patient safety limit compliance study requirement patient symptomatic brain metastasis ( patient history brain metastasis must clinically stable take steroid ; anticonvulsant allow ) A serious nonhealing active wound , ulcer , bone fracture Known human immunodeficiency viruspositive A history hemorrhagic thrombotic disorder within 9 month Pregnant breast feed A history prior treatment agent specifically target IGFRs . Known diabetes Inability unwillingness interrupt steroidal hormonal therapy duration treatment IMCA12 A positive antiIMCA12 antibody response A history allergic reaction monoclonal antibody therapeutic protein Employees investigator study center direct involvement study study direction investigator study center , well family member employee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
</DOC>